Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical, Inc.

Barclays analyst Jenna Davidner reiterated a Buy rating on Collegium Pharmaceutical yesterday and set a price target of $48.00. The company’s share...

Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Adicet Bio (ACET...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COLL	$23.53	-0.72%	884.07K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	COLL	$23.53	-0.7%	884.07K
3
4
5
6

COLL

Get Collegium Pharmaceutical, Inc. Data in Excel

Get Collegium Pharmaceutical, Inc. Data in Excel